NVAC 02-04-04 W. R. Dowdle. Laboratory Containment of Wild Poliovirus in the United States Phase I National Survey and Inventory Final Report January.

Slides:



Advertisements
Similar presentations
1 |1 | Countries using and planning to introduce IPV July 2014 status report This slide deck provides a summary per country on the status of planning for.
Advertisements

1 |1 | Countries using and planning to introduce IPV.
Monitoring progress towards the coverage and disease incidence targets GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING March 2011 Geneva, Switzerland.
1 |1 | Countries using and planning to introduce IPV.
1 |1 | Countries using and planning to introduce IPV.
Vaccine in National Immunization Programme Update March 2015.
1 |1 | Countries using and planning to introduce IPV.
Partnerships improving access to science journals in the developing world: Nicole Joos, TEEAL Project Manager Mann Library May 2006 TEEAL, AGORA and HINARI.
1 |1 | Countries using and planning to introduce IPV.
World Health Organization
1 |1 | Countries using and planning to introduce IPV.
TITLE from VIEW and SLIDE MASTER | August 7, |1 | Countries with Hib vaccine in the national immunization programme; and planned introductions *
WHO Regional Office for Europe Vaccine preventable diseases and Immunization programme Measles containing vaccine (MCV1) coverage in the WHO European Region.
The Global Plan to Stop TB, (1)
World Health Organization
National Immunization Program Report NVAC Washington, DC  February 3-4, 2004 Stephen L. Cochi, M.D., M.P.H. Acting Director, National Immunization Program.
Polio Update Pre Tender Meeting 11 th December 2008 UNICEF Supply Division.
Progress towards Sustainable Measles Mortality Reduction South-East Asia Region Jayantha Liyanage Medical Officer- EPI Immunization and Vaccine Development.
Inter-Departmental Working Group
1 |1 | Countries using and planning to introduce IPV.
Adverse Events following Immunization (AEFI) Monitoring and Causality Assessment An Overview Department of Disease Control Ministry of Public Health Bureau.
Highlights of New WPV Cases 34 new cases in 5 countries 14 cases (14 W3) but no new district in India Most recent date of onset 03 Oct 1 case (W1) but.
Data in WHO HQ as of 09 October 2012 Highlights of New Wild Poliovirus Cases The boundaries and names shown and the designations used in the maps in this.
Evidence and Information for Policy Christopher J.L. Murray Executive Director Evidence and Information for Policy World Health Organization National Capacity.
8 th Global Measles and Rubella LabNet Meeting, Sept 2010 Key Recommendations GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING March 2011 Salle B, WHO.
Data in WHO HQ as of 17 Apr 2012 Highlights of New Wild Poliovirus Cases The boundaries and names shown and the designations used in the maps in this document.
WHO and International Panel International Collaborative Effort on Injury Statistics Hyatt Regency, Washington September 7-8, 2006.
NVAC The Global Certification Commission declares the world polio-free when: No wild poliovirus has been found for at least 3 consecutive years.
Measles Mortality Reduction: the risk of resurgence Global Immunization Meeting Geneva, Switzerland 1-3 February 2010 Balcha Masresha, WHO/AFRO.
Global Programme on Evidence for Health Policy The use of GIS in the Global Programme on Evidence for Health Policy (GPE) Meeting on Cartography and Geographic.
Vaccine in National Immunization Programme Update April 2016.
World Health Organization
Data quality for polio eradication: Accuracy & reliability
SAGE 2010 Sampling Distribution
reporting rate of discarded cases* per 100'000 population**
World Health Organization
PROGRESS IN GLOBAL TB CONTROL
Monthly Distribution of Wild Poliovirus Cases1,
SAGE 2009 Sampling Distribution
06/12/2018 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Countries Having Introduced Hib Vaccine
Countries Having Introduced Hib Vaccine and Infant Hib Coverage, 2010
Sampling Distribution
15/01/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week The boundaries and names shown and the designations used in.
Non-polio AFP Rate July 2014 – June 2015 July 2015 – June 2016
Monthly Distribution of Wild Poliovirus Cases1,
(70 countries or 36%) (23 countries or 12%)
Countries with Genotype data available
Countries Using Hib Vaccine in National Immunization Schedule in 2010 and Countries Approved for GAVI Support for Use from 2011 Onwards Yes (166 countries.
World Health Organization
24/02/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
World Health Organization
Onset of most recent WPV1 Case Number of WPV infected districts
08/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Countries having introduced HepB vaccine
No new positives this week
05/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Most-affected regions in the Russian Federation
08/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week The boundaries and names shown and the designations used in.
Mapping Levels of Palliative Care Development: A Global Update
Countries Using Mening Vaccine in National Immunization Schedule 2011
- Use same categories as for bar chart below Introduced Without GAVI
Onset of most recent case Number of infected districts
04/05/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1contacts of positive AFP cases, community, healthy children.
Meningitis/Encephalitis Surveillance Countries reporting to WHO Network or with Other (non-WHO Network) Surveillance Activities WHO Network (46 member.
16/05/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
27/08/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
2,100 4,200 1,050 Kilometers < 90% (75 countries or 39%)
World Health Organization
World Health Organization
Presentation transcript:

NVAC W. R. Dowdle

Laboratory Containment of Wild Poliovirus in the United States Phase I National Survey and Inventory Final Report January 15, 2004

The Purpose of Laboratory Containment To minimize the risk of reintroducing wild polioviruses into the community after eradication 2nd edition 2003

Purpose of Phase I To encourage labs to dispose of unneeded wild poliovirus materials Establish National Inventories of laboratories retaining such materials.

US Survey and Inventory Began in October 2001 NVPO through contract with the Task Force for Child Survival and Development Working in partnership with CDC

Steps in the survey process Develop the Action Plan Authorize the survey (WHO, HHS, OMB) Enlist support of laboratory community Perform pilot surveys (x2) Establish database of institutions/labs Develop survey instruments Implement the survey

Database: Categories of Institutions CLIA Certified Non-Complex Testing Most likely to possess (1,216) Least likely to possess (26,844) CLIA Certified Complex Testing May possess (4,369) Academic Federal Government Industry State and Local Government Hospitals Private Labs

Survey Database (Institutions) Yet to Respond Most likely to possess ## Academic 4370 Federal Government 130 Industrial 6680 State & Local Government 980 Subtotal 1,2160 May possess CLIA certified complex testing 4,3690 Least likely to possess CLIA certified non-complex testing 26,8442,638 Total32,429 † 0 Results of National Survey* * November 2003 † Represents a total of 105,356 laboratories surveyed

Finding no WPV materials among 24,206 responders confirmed small clinical labs were unlikely risks. Follow-up of “least likely” labs discontinued per NVAC workgroup.

Institutions Retain- ing Materials Laboratories Retaining Materials Most likely to possess #InfectiousPotential Infectious BothTotal Academic Federal Government Industrial State & Local Government Subtotal May possess CLIA certified complex testing Least likely to possess CLIA certified non-complex testing Total Number of institutions on National Inventory/ Types of materials retained* * As of November 2003

Post-survey literature search To confirm that all institutions/laboratories publishing on wild poliovirus materials are on the National Inventory To identify laboratories publishing on infectious agents that share common enteric origins or replicate on poliovirus-permissive systems.

Selected PubMed Literature Search 2002 & 2003 Bacterial and Viral n = 1906

Sensitivity of search of >12,000 citations ( ) CategoryInventorySearchPercent Academic Fed. Gov Industry24625 State & local Totals

Institutions publishing ( ) on any poliovirus and not listed on survey database 1 community college, environmental project now discontinued 1 biotech startup, now defunct

Institutions publishing ( ) on associated viruses and not listed on survey database 1 water service Co. R&D lab 2 non-profit foundation laboratories 1 community college 2 biotech startups, 1 now defunct

Summary ( Phase I) The US national survey of >32,000 institutions and >105,000 labs is complete. The quality and completeness of the survey is validated by a10 year literature search The National Inventory consists of 122 institutions with180 labs. Recommendations for Phase II are made and responsibilities defined in the Report

Acknowledgements Kim Koporc (TFSCD), Sandra Browning and Alison Mawle (CDC) CDC advisors and support staff Departments of the Executive Branch Thousands of administrative and lab staff NVAC Polio Laboratory Containment Workgroup

Next steps HHS submits Phase I report to PAHO US begins planning for Phase II

Wild Poliovirus*, 24 Dec 2002 to 23 Dec 2003 Data in WHO HQ as of 23 Dec 2003 *Excludes viruses detected from environmental surveillance and vaccine derived polio viruses. The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.  WHO All rights reserved Case or outbreak following importation Endemic countries Wild virus type 1 Wild virus type 3 Wild virus type 1 and 3